Investigational drug · Phase 3
Pelacarsen
Also called: TQJ230
Not approved by FDA. In 7 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Cardiovascular Disease and Lipoprotein(a), Atherosclerotic Cardiovascular Disease (ASCVD), Atherosclerotic Cardiovascular Disease.
Phase 3Last checked: Nov 19, 2026Latest source record: Oct 14, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
7
4 still active
All registered trials
14
Any phase or sponsor naming "Pelacarsen"
First trial start
2019
Dec 12, 2019
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Pelacarsen", any sponsor or status.
Conditions studied
As listed on its trial records.
- Cardiovascular Disease and Lipoprotein(a)
- Atherosclerotic Cardiovascular Disease (ASCVD)
- Atherosclerotic Cardiovascular Disease
- Aortic Stenosis
- Hyperlipoproteinemia(a)
- Elevated Lp(a) and Established Atherosclerotic Cardiovascular Disease
Approved drugs for the same conditions: Cardiovascular and metabolic
Largest trials
Live from ClinicalTrials.gov: studies naming "Pelacarsen" as an intervention, largest first.
- Assessing the Impact of Lipoprotein (a) Lowering With Pelacarsen (TQJ230) on Major Cardiovascular Events in Patients With CVDPivotal-lookingCompleted
Novartis PharmaceuticalsNovartis (NVS)
NCT04023552 · 8,323 participants · Start Dec 12, 2019 · Primary completion Jul 16, 2026
Drug: TQJ230; Placebo · For: Cardiovascular Disease and Lipoprotein(a)
Sites: Andalusia, Alabama; Birmingham, Alabama; Huntsville, Alabama · 902 sites in all
- An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230)Pivotal-lookingActive, not recruiting
Novartis PharmaceuticalsNovartis (NVS)
NCT07517263 · 5,700 participants (planned) · Start May 11, 2026 · Primary completion Jan 9, 2030
Drug: Pelacarsen (TQJ230) · For: Cardiovascular Disease and Lipoprotein(a)
Sites: Andalusia, Alabama; Huntsville, Alabama; Mobile, Alabama · 646 sites in all
- Pelacarsen Roll-over Extension ProgramPivotal-lookingActive, not recruiting
Novartis PharmaceuticalsNovartis (NVS)
NCT06875973 · 599 participants (planned) · Start May 19, 2025 · Primary completion Dec 8, 2030
Drug: Pelacarsen (TQJ230) · For: Atherosclerotic Cardiovascular Disease
Sites: Birmingham, Alabama; Little Rock, Arkansas; Beverly Hills, California · 89 sites in all
- A Multicenter Trial Assessing the Impact of Lipoprotein(a) Lowering With Pelacarsen (TQJ230) on the Progression of Calcific Aortic Valve StenosisPivotal-lookingRecruiting
Novartis PharmaceuticalsNovartis (NVS)
NCT05646381 · 502 participants (planned) · Start Mar 7, 2024 · Primary completion Mar 12, 2030
Drug: Pelacarsen (TQJ230) 80mg; Matching placebo · For: Aortic Stenosis
Sites: Huntsville, Alabama; Beverly Hills, California; Covina, California · 140 sites in all
- Lp(a) Lowering Study of Pelacarsen (TQJ230) in US Black/African American and Hispanic Participants With Elevated Lp(a) and Established ASCVDPivotal-lookingCompleted
Novartis PharmaceuticalsNovartis (NVS)
NCT06267560 · 422 participants · Start Apr 24, 2024 · Primary completion Mar 25, 2026
Drug: TQJ230; Placebo · For: Elevated Lp(a) and Established Atherosclerotic Cardiovascular Disease
Sites: Birmingham, Alabama; Little Rock, Arkansas; Beverly Hills, California · 96 sites in all
- Phase 2 Study of ISIS 681257 (AKCEA-APO(a)-LRx) in Participants With Hyperlipoproteinemia(a) and Cardiovascular DiseasePivotal-lookingCompleted
Akcea TherapeuticsIndustry
NCT03070782 · 286 participants · Start Mar 7, 2017 · Primary completion Jul 26, 2018
Drug: ISIS 681257; Placebo · For: Elevated Lipoprotein(a); Cardiovascular Disease
Sites: Cottonwood, Arizona; Huntington Beach, California; La Jolla, California · 32 sites in all
- Lp(a) Lowering Study of Pelacarsen (TQJ230) With Background Inclisiran in Participants With Elevated Lp(a) and Established ASCVDPivotal-lookingActive, not recruiting
Novartis PharmaceuticalsNovartis (NVS)
NCT06813911 · 246 participants · Start Apr 30, 2025 · Primary completion Feb 3, 2028
Drug: Pelacarsen; Placebo and 1 more · For: Atherosclerotic Cardiovascular Disease (ASCVD)
Sites: Birmingham, Alabama; Sun City West, Arizona; Beverly Hills, California · 94 sites in all
Novartis PharmaceuticalsNovartis (NVS)
NCT05305664 · 51 participants · Start Aug 19, 2022 · Primary completion Jan 28, 2025
Drug: Pelacarsen (TQJ230) 80 mg s.c.; Corresponding Placebo · For: Hyperlipoproteinemia(a)
Sites: Villingen-Schwenningen, Germany; Munich, Germany; Würzburg, Germany · 13 sites in all
- An Open Label Extension (OLE) Study to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230)Pivotal-lookingTerminated
Novartis PharmaceuticalsNovartis (NVS)
NCT05900141 · 41 participants · Start Sep 29, 2023 · Primary completion Oct 15, 2026
Drug: Pelacarsen · For: Hyperlipoproteinemia (a)
Sites: Munich, Germany; Würzburg, Germany; Frankfurt am Main, Germany · 9 sites in all
Ionis Pharmaceuticals, Inc.Ionis Pharmaceuticals (IONS)
NCT05337878 · 29 participants · Start Oct 15, 2018 · Primary completion Dec 18, 2019
Drug: Placebo; Pelacarsen · For: Healthy Participants
Sites: Glendale, California
Newest research
PubMed records naming it or its code names, newest first.
- Lipoprotein(a) in Cardiovascular Disease: Integrating Epidemiology, Clinical Guidelines, Molar Measurement, and Emerging Therapies.
Thomas PE, Vedel-Krogh S, Kronenberg F, et al. · Clin Chem 2026
- Lp(a)-Reducing Agent Pelacarsen Misses the Mark in Phase 3-Now What?
Abbasi J · JAMA 2026
- Efficacy and Safety of Pelacarsen in Black/African American and Hispanic Participants with Elevated Lipoprotein(a) and Established Atherosclerotic Cardiovascular Disease: The Randomized Controlled Lp(a)FRONTIERS EXPANSION Study.
Ferdinand KC, Rodriguez F, Baldari D, et al. · Circ Popul Health Outcomes 2026
- Pelacarsen and Cardiovascular Outcomes in Patients with High Lipoprotein(a).
Cho L, Nicholls SJ, Frndak S, et al. · N Engl J Med 2026
- Extended Analyses of Pelacarsen and Cardiovascular Outcomes in Patients with High Lipoprotein(a).
Nissen SE, Cho L, Frndak S, et al. · NEJM Evid 2026
- RNA-Targeted Therapeutics in Cardiovascular Risk Reduction: From Gene Silencing to Precision Cardiology.
Karim A, Binte Imran S, Yousuf YM, et al. · Cardiol Rev 2026
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Novartis.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.